Chi­nese rare dis­ease play­er inks first deal around nar­colep­sy drug Wak­ix af­ter grab­bing $80M to build an ecosys­tem

Two months ago, the nar­colep­sy ther­a­py Wak­ix pro­pelled Har­mo­ny Bio­sciences to a $128 mil­lion de­but on Nas­daq. Now, the same drug is serv­ing as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA